Skip to main content
SpringerLink
Log in

Management of Liver Metastases of Gastrointestinal Stromal Tumors

  • Chapter
  • First Online:
Gastrointestinal Stromal Tumors

  • 940 Accesses

Abstract

Gastrointestinal stromal tumor (GIST) has propensity for metastatic spread to the liver. GIST liver metastases should be identified early and treated aggressively when possible. Combinations of tyrosine kinase inhibitors (TKIs) and aggressive surgical resection are current mainstays of therapy. Appropriate patient selection based on presentation and TKI response guides therapy. Salvage therapy may be possible for patients with GIST patients with hepatic metastases. This chapter reviews the clinical decision-making necessary for effective management of GIST hepatic metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CT:

Computerized tomography

GIST:

Gastrointestinal stromal tumor

MRI:

Magnetic resonance imaging

NCCN:

National Comprehensive Cancer Network

PET:

Positron emission tomography

PFS:

Progression-free survival

RFA:

Radiofrequency ablation

TKI:

Tyrosine kinase inhibitors

XRT:

External-beam radiation therapy

References

  1. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cheung TT, Chok KS, Chan AC, et al. Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour. ANZ J Surg. 2014;84(11):827–31.

    Article  PubMed  Google Scholar 

  3. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–9.

    Article  PubMed  Google Scholar 

  4. Yu MH, Lee JM, Baek JH, et al. MRI features of gastrointestinal stromal tumors. AJR Am J Roentgenol. 2014;203(5):980–91.

    Article  PubMed  Google Scholar 

  5. Ye YJ, Gao ZD, Poston GJ, et al. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol. 2009;35(8):787–92.

    Article  PubMed  Google Scholar 

  6. Pisters PW, Patel SR. Gastrointestinal stromal tumors: current management. J Surg Oncol. 2010;102(5):530–8.

    Article  PubMed  Google Scholar 

  7. Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am. 2009;23(1):115–27, ix.

    Article  PubMed  Google Scholar 

  8. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1–41; quiz S42-44.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.

    Article  PubMed  Google Scholar 

  10. Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008;15(8):2153–63.

    Article  PubMed  Google Scholar 

  11. Raut CP, Wang Q, Manola J, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010;17(2):407–15.

    Article  PubMed  Google Scholar 

  12. Mussi C, Ronellenfitsch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21(2):403–8.

    Article  CAS  PubMed  Google Scholar 

  13. Rathmann N, Diehl SJ, Dinter D, et al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors. J Vasc Interv Radiol. 2015;26(2):231–8.

    Article  PubMed  Google Scholar 

  14. Cao G, Zhu X, Li J, et al. A comparative study between Embosphere((R)) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. Chin J Cancer Res. 2014;26(1):124–31.

    PubMed  PubMed Central  Google Scholar 

  15. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.

    Article  CAS  PubMed  Google Scholar 

  16. Sciot R, Debiec-Rychter M, Daugaard S, et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer. 2008;44(13):1855–60.

    Article  PubMed  Google Scholar 

  17. Hong X, Choi H, Loyer EM, et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics. 2006;26(2):481–95.

    Article  PubMed  Google Scholar 

  18. Bauer S, Joensuu H. Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: current status and future directions. Drugs. 2015;75(12):1323–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.

    Article  CAS  PubMed  Google Scholar 

  20. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9.

    Article  CAS  PubMed  Google Scholar 

  21. Eisenberg BL, Pipas JM. Gastrointestinal stromal tumor--background, pathology, treatment. Hematol Oncol Clin North Am. 2012;26(6):1239–59.

    Article  PubMed  Google Scholar 

  22. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  CAS  PubMed  Google Scholar 

  25. Hsu CC, Wu CE, Chen JS, et al. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients. Anticancer Res. 2014;34(9):5029–36.

    CAS  PubMed  Google Scholar 

  26. Nunobe S, Sano T, Shimada K, et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol. 2005;35(6):338–41.

    Article  PubMed  Google Scholar 

  27. Brudvik KW, Patel SH, Roland CL, et al. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg. 2015;19(8):1476–83.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zaydfudim V, Okuno SH, Que FG, et al. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. J Surg Res. 2012;177(2):248–54.

    Article  PubMed  Google Scholar 

  29. Cananzi FC, Belgaumkar AP, Lorenzi B, et al. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. ANZ J Surg. 2014;84(12):E1–8.

    Article  PubMed  Google Scholar 

  30. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5 Suppl 2:S1–29; quiz S30.

    PubMed  Google Scholar 

  31. Xia L, Zhang MM, Ji L, et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010;40(10):936–42.

    Article  CAS  PubMed  Google Scholar 

  32. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245(3):341–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24(15):2325–31.

    Article  CAS  PubMed  Google Scholar 

  34. Maehara N, Chijiiwa K, Eto T, et al. Surgical treatment for gastric GIST with special reference to liver metastases. Hepatogastroenterology. 2008;55(82–83):512–6.

    PubMed  Google Scholar 

  35. Pantaleo MA, Di Battista M, Catena F, et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol. 2008;134(5):625–30.

    Article  CAS  PubMed  Google Scholar 

  36. Guiteau J, Fanucchi M, Folpe A, et al. Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg. 2006;72(12):1225–30.

    PubMed  Google Scholar 

  37. de la Fuente SG, Deneve JL, Parsons CM, et al. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford). 2013;15(9):655–60.

    Article  Google Scholar 

  38. Serralta AS, Sanjuan FR, Moya AH, et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol. 2004;16(11):1237–9.

    Article  CAS  PubMed  Google Scholar 

  39. Zhu J, Yang Y, Zhou L, et al. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer. 2010;10:199.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Zhu J, Wang Y, Hou M, et al. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology. 2007;73(5–6):324–7.

    Article  CAS  PubMed  Google Scholar 

  41. Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.

    Article  PubMed  Google Scholar 

  42. Joensuu H, Eriksson M, Collan J, et al. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study. Radiother Oncol. 2015;116(2):233–8.

    Article  CAS  PubMed  Google Scholar 

  43. Yamanaka T, Takaki H, Nakatsuka A, et al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol. 2013;24(3):341–6.

    Article  PubMed  Google Scholar 

  44. Hakime A, Le Cesne A, Deschamps F, et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol. 2014;37(1):132–9.

    Article  PubMed  Google Scholar 

  45. Takaki H, Litchman T, Covey A, et al. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer. 2014;45(4):494–9.

    Article  CAS  PubMed  Google Scholar 

  46. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245(3):347–52.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Turley RS, Peng PD, Reddy SK, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118(14):3571–8.

    Article  PubMed  Google Scholar 

  48. Rubio-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015;22(9):2948–57.

    Article  PubMed  Google Scholar 

  49. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365C Clifton Road NE, 2nd Floor, Atlanta, GA, 30322, USA

    Andrew D. Morris MD, Shishir K. Maithel MD, FACS & David A. Kooby MD, FACS

Authors
  1. Andrew D. Morris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shishir K. Maithel MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Kooby MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Kooby MD, FACS .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Louisville, Louisville, Kentucky, USA

    Charles R. Scoggins

  2. Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Chandrajit P. Raut

  3. Harvard Medical School, Boston, Massachusetts, USA

    John T. Mullen

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morris, A.D., Maithel, S.K., Kooby, D.A. (2017). Management of Liver Metastases of Gastrointestinal Stromal Tumors. In: Scoggins, C., Raut, C., Mullen, J. (eds) Gastrointestinal Stromal Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-42632-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42632-7_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42630-3

  • Online ISBN: 978-3-319-42632-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation